GT BIOPHARMA, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $-27.5M | $5.3M |
| FY2021 | — | $21.9M | $9.0M |
| FY2022 | — | $11.7M | $5.7M |
| FY2023 | — | $7.5M | $1.1M |
| FY2024 | — | $-1.7M | $4.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $-27.5M | $5.3M |
| FY2021 | — | $21.9M | $9.0M |
| FY2022 | — | $11.7M | $5.7M |
| FY2023 | — | $7.5M | $1.1M |
| FY2024 | — | $-1.7M | $4.0M |